VivoSeq
Other

FDC

5

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

FDC is an early-stage landscape with 5 programs across 3 companies. The most active players are Basilea Pharmaceutica, Dexcel Pharma Technologies Ltd., Iterum Therapeutics, International Limited.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Basilea Pharmaceutica logo

Basilea Pharmaceutica

2 programs

Phase 1D

Dexcel Pharma Technologies Ltd.

1 program

Phase 1I

Iterum Therapeutics, International Limited

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 1, Open-label Study to Evaluate the Safety and to Characterize the Pharmacokinetics of a Fixed-Dose Combination Formulation of Ceftibuten-Ledaborbactam Etzadroxil
Recruiting·Basilea Pharmaceutica logoBasilea Pharmaceutica·Phase 1·NCT06733675·96 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)